Holen Sie sich die Stockscreener-App
1.405
10.70%
-0.165
Schlusskurs vom Vortag:
$1.57
Offen:
$1.45
24-Stunden-Volumen:
316.49K
Relative Volume:
1.56
Marktkapitalisierung:
$3.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+11.27%
1M Leistung:
-13.72%
6M Leistung:
-62.71%
1J Leistung:
-92.62%
1-Tages-Spanne:
$1.3203
$1.46
1-Wochen-Bereich:
$1.23
$2.43
52-Wochen-Spanne:
$1.14
$42.40
Autonomix Medical Inc Stock (AMIX) Company Profile
Firmenname
Autonomix Medical Inc
Sektor
Branche
Telefon
832-277-7816
Adresse
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Vergleichen Sie AMIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
1.402 | 3.99M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
136.50 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.86 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
398.17 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.13 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.79 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Autonomix Medical Inc Aktie (AMIX) Neueste Nachrichten
Citadel Advisors LLC Makes New $180,000 Investment in Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
Autonomix set to expand cancer pain treatment trial - Investing.com India
Autonomix set to expand cancer pain treatment trial By Investing.com - Investing.com South Africa
Autonomix granted approval to expand PoC human clinical trial - TipRanks
Autonomix (AMIX) Gains Approval for New Clinical Trial Phase in Uzbekistan | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Granted Approval to Expand - GlobeNewswire
Autonomix Medical Expands Revolutionary Cancer Pain Trial Beyond Pancreatic to Multiple Visceral Cancers - Stock Titan
Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Large Decrease in Short Interest - Defense World
Autonomix Medical, Inc. SEC 10-K Report - TradingView
Autonomix Medical (NASDAQ:AMIX) Stock Price Down 4.3% – What’s Next? - Defense World
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - MSN
Autonomix picks up key nerve ablation catheter patent - MassDevice
Autonomix granted key U.S. patent for catheter-based platform technology - TipRanks
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technolo - GuruFocus
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technology | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - The Manila Times
Breakthrough Patent: How Autonomix Medical's New Nerve-Mapping Tech Could Transform Pain Treatment - Stock Titan
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event - GlobeNewswire
Exclusive Live Access: Autonomix CEO Reveals Game-Changing Neural Sensing Technology to Investors - Stock Titan
Autonomix CEO outlines follow-on expansion study expected to begin in Q2 - TipRanks
Autonomix plans expansion phase for cancer pain trial - Investing.com
AMIX Expands Clinical Trials to Target Broader Cancer Pain Marke - GuruFocus
AMIX Expands Clinical Trials to Target Broader Cancer Pain Market | AMIX Stock News - GuruFocus
Autonomix plans expansion phase for cancer pain trial By Investing.com - Investing.com India
Autonomix Medical, Inc. Announces Follow-On Phase of Clinical Trial to Expand Treatment Options for Cancer Pain Management - Nasdaq
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines - GlobeNewswire
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - Stock Titan
Ananda Pharma, Accsys Technologies, Autonomix Medical, BitwiseSmall Cap Week in Review - Research Tree
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive financial news
Autonomix reports significant pain relief in cancer trial - Investing.com
Autonomix reports significant pain relief in cancer trial By Investing.com - Investing.com India
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain - GlobeNewswire
Breakthrough Cancer Pain Treatment Eliminates Opioid Use in 100% of Responding Patients, Trial Shows - Stock Titan
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic Cancer Pain Treatment | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com Australia
Autonomix advances pain treatment in cancer trials - Investing.com
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Finanzdaten der Autonomix Medical Inc-Aktie (AMIX)
Es liegen keine Finanzdaten für Autonomix Medical Inc (AMIX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):